Central actions of angiotensin play an important role in cardiovascular control and have been implicated in the pathogenesis of hypertension and heart failure. One feature of centrally or peripherally administered angiotensin is that the bradycardia in response to an acute pressor effect is blunted. It is unknown whether following central angiotensin this is due partly to increased cardiac sympathetic nerve activity (CSNA). We recorded CSNA and arterial pressure in conscious sheep, at least 3 days after electrode implantation. The effects of intracerebroventricular (ICV) infusions of angiotensin II (3nmol/h for 30 min) and artificial cerebrospinal fluid (CSF) (1mL/h) were determined. The response to ICV hypertonic saline (0.6M NaCl in CSF at 1 mL/h) was examined as there is evidence that hypertonic saline acts via angiotensinergic pathways. ICV angiotensin increased CSNA by 23±7% (P<0.001) and mean arterial pressure (MAP) by 7.6±1.2 mmHg (P<0.001) but did not significantly change heart rate (n=5). During ICV Ang II the reflex relation between CSNA and diastolic blood pressure was significantly shifted to the right (P<0.01). ICV hypertonic saline increased CSNA (+9.4±6.6%, P<0.05) and MAP but did not alter heart rate. The responses to angiotensin and hypertonic saline were prevented by ICV losartan (1 mg/h). In conclusion, in conscious sheep angiotensin acts within the brain to increase CSNA, despite increased MAP.
INTRODUCTION
Actions of angiotensin II on the brain play an important role in cardiovascular control and have been implicated in the pathogenesis of hypertension and heart failure (5, 14, 26, 34) . The central effects of Ang II result from its actions both as a circulating hormone acting on the circumventricular organs and as neurotransmitter acting behind the blood-brain-barrier. One of the important actions of Ang II, given via either route, is impairment of baroreflex sensitivity (4, 33) . These actions of Ang II are inhibited by losartan, indicating that they are mediated by Ang II AT-1 receptors (17, 33) .
The acute pressor response to intravenous administration of Ang II is due to its vasoconstrictor action and is accompanied by impaired reflex bradycardia (9, 18) . This results from attenuation of the baroreflex induced increase in vagal discharge by an action of Ang II on the area postrema (13, 16) . Following intravenous Ang II there is no evidence that sympathetic activity to the heart is increased (7, 9) and other evidence indicates that the acute pressor response is not mediated by increased sympathetic activity (28) . In contrast, the pressor response to intracerebroventricular (ICV) administration of Ang II is mediated by increased sympathetic vasoconstrictor activity and vasopressin release (2, 8, 32) . As with intravenous administration of Ang II, the pressor response is accompanied by an impaired bradycardia, which was proposed to result from attenuation by Ang II of baroreflex induced increases in vagal tone (4) . It is, however, unknown whether central administration of Ang II has any effect on cardiac sympathetic nerve activity (CSNA).
One role for central angiotensinergic mechanisms in the brain is to mediate the cardiovascular, endocrine and osmoregulatory responses to increases in brain sodium concentration. Central administration of hypertonic saline elicits a range of losartan-sensitive cardiovascular and osmoregulatory responses, including an increase in arterial pressure, inhibition of renal nerve sympathetic activity (RSNA) and renin release, natriuresis, and drinking (1, 18, 23, 30) , indicating a role for angiotensin AT-1 receptors. Furthermore, central administration of Ang II mimics the effects of hypertonic saline (1, 17, 30) , suggesting that these stimuli act on the same neural pathways in the brain.
To investigate whether centrally administered Ang II or hypertonic saline increase sympathetic outflow to the heart, we have examined the effect of these stimuli on directly measured CSNA in conscious sheep. It is particularly important to measure CSNA in the conscious state because CSNA is suppressed more than other sympathetic outflows by anesthesia (15) . In addition, the effect of losartan on these responses has been examined to establish whether they are mediated by AT-1 receptors. To allow comparison of the effects of central administration of hypertonic saline and Ang II on the activity and baroreflex control of the cardiac and renal sympathetic nerves, we used identical protocols to those used previously to determine the effects of these stimuli on RSNA (17, 18) .
METHODS
Adult merino ewes (35-45 kg body weight), oophorectomised and with carotid arteries enclosed in skin loops, were housed in individual metabolism cages in association with other sheep. They were not used until they were accustomed to laboratory conditions and human contact. Sheep were fed a diet of oaten chaff (800 g/day) and water was offered ad libitum.
Experiments were conducted with the sheep standing, and access to water was removed during the experimental period. All experiments were approved by the Animal Experimentation Ethics Committee of the Howard Florey Institute.
Surgical procedures.
Anaesthesia was induced with intravenous (IV) sodium thiopental (15 mg/kg) and following intubation was maintained with 1.5-2.0% isoflurane/O 2 . Animals were placed in a stereotaxic apparatus and stainless steel guide tubes were implanted over the lateral cerebral ventricles.
After at least 2 weeks recovery and on the day before implantation of recording electrodes, a sterile Tygon cannula (ID 1.0mm, OD 1.5mm) was inserted under aseptic conditions15-20 cm into a carotid artery, towards the heart, for the measurement of arterial pressure. Under local anaesthesia, a sterile polyethelene cannula (ID 0.58mm, OD 0.97mm) was inserted 15 cm into the jugular vein for intravenous (IV) infusion. The patency of the cannulae was maintained by infusing heparinised saline (25 U/mL) at 3.0 mL/hr from flush devices (TDF-3WC.
Biosensors International, Singapore). The cannula for measurement of arterial pressure was connected to a pressure transducer (TDXIII. Cobe, Colorado, USA) tied to the wool on the sheep's back. The arterial pressure was corrected to compensate for the height of the transducer above the level of the heart. Heart rate (HR) was recorded with a cardiotachometer triggered by the arterial pressure waveform.
Under general anaesthesia, electrodes were implanted in the left cardiothoracic nerves (10) .
Briefly, an incision was made above the 4 th rib, the periosteum was opened and the rib removed. The thorax was held open with a rib retractor, and the lungs were held back with wet packs. Using a binocular microscope the thoracic cardiac nerves were identified and the facia over the nerves was removed. Electrodes consisted of stainless steel entomological pins (0.05mm diameter) etched to a fine point, glued into the end of teflon-coated 25 strand silver coated copper wire (CZ1174SPC. Cooner Wire, Chatsworth, CA) (17, 18) . The exposed tip of the electrode (1.5-2.0 mm in length) was pushed obliquely through the nerve sheath, ensuring that the tip was positioned in the center of the nerve. Up to 5 electrodes were implanted into the nerve and fixed in place with cyanoacrylate glue. The implantation site was covered with a layer of Kwik-Sil (WPI, Glen Waverly, Victoria, Australia) and the wires were exteriorised through the sutured wound. A stainless steel suture looped through the skin was used as an earth. Experiments were conducted on standing, conscious sheep, and to minimise any effect of surgical stress were started on the third day after implantation of the electrodes.
Nerve recording
Sympathetic nerve activity was recorded differentially between pairs of electrodes, and the pair with the best signal to noise ratio was selected. The signal was amplified (x100,000) and filtered (bandpass 400 to1000 Hz), displayed on an oscilloscope and passed through an audio amplifier and loud speaker. Spikes above the noise level were detected with a discriminator (17) . Sympathetic nerve activity, spike counts and blood pressure were recorded on computer using a CED micro 1401 interface and Spike 2 software (Cambridge Electronic Design, UK).
Spike counts (in 10 second bins) were also plotted on a chart recorder (Gould RS3400), together with MAP and heart rate (HR).
Experimental protocols.

Ganglion blockade
Ganglion blockade with hexamethonium (125 mg/h for 2 hours) was infused to confirm that nerve activity was recorded from post-ganglionic sympathetic nerves. We have demonstrated previously that this dose of hexamethonium inhibits RSNA (17) .
ICV infusions
Prior to infusion into the lateral cerebral ventricles (ICV) the cap was removed from one of the guide tubes and a sterile probe (20 gauge needle with luer lock fitting) of appropriate length was inserted through the guide tube into a lateral cerebral ventricle. A sterile polyethelene cannula filled with artificial cerebrospinal fluid (CSF) and joined to a syringe pump (Braun) was connected to the probe. The probe was considered patent if CSF flowed freely into and back from the ventricle under hydrostatic pressure, as the tubing was raised or lowered in relation to the ventricle. All solutions for ICV infusion were filtered through a sterile 0.22 µm filter before administration and were given at 1 mL/h. Infusions of the test solutions were started following a 10 min stable control period. Not all experiments were performed in all sheep, because the order in which the treatments were given was randomised and the recording signal had deteriorated in some cases before all the experiments were completed.
Effect of ICV infusion of losartan on the responses to ICV Ang II
Ang II (Human, Auspep; 3 nmol/mL), dissolved in CSF, was infused ICV for 30 min at 1 mL/h in 6 conscious sheep. CSNA and MAP were measured during the control period, during the infusion and for up to 2 hours afterwards. Two hours after the end of the ICV infusion of Ang II (3 nmol/h) or when all parameters had returned to control for at least 30 minutes, an ICV infusion of losartan (Dupont-Merk; 1 mg/mL in CSF) was commenced.
After 1 hour of ICV infusion of losartan, Ang II (3 nmol/h) was infused ICV together with losartan for 30 min. Recordings were continued for 60 min after the end of the infusion.
Control experiments in which artificial CSF was infused at 1mL/h for 30 min were also performed.
Effect of ICV losartan on the responses to ICV hypertonic saline
CSNA and MAP were measured during the 10 minute control period, during ICV infusion of CSF containing 0.6M NaCl at 1mL/h for 20 min, and during the 20 min post infusion period in 7 conscious sheep. ICV infusion of losartan (Dupont-Merck; 1mg/mL in CSF, infused at 1mL/h) was commenced a minimum of 40 min after the end of the ICV hypertonic saline, when all variables had returned to control. The dose of losartan used has been shown to inhibit the effect of ICV Ang II (10 nmol/h) on RSNA, MAP and plasma renin activity in conscious sheep (17) . After infusion of losartan for 1 hour, 0.6M NaCl in CSF containing losartan (1 mg/mL) was infused at 1 mL/h for 20 min. Recordings were continued for 30 min after the end of the infusion.
As an osmotic control for the infusion of CSF containing 0.6M NaCl, the effects of ICV infusion of hyperosmotic CSF (0.9M sorbitol in CSF at 1 mL/h) were examined, using the same protocol as that used for ICV hypertonic saline. Control experiments in which CSF was infused at 1mL/h for 30 min were also completed.
Baroreflex relations
The baroreflex relations between CSNA and diastolic pressure, during ICV infusion of Ang II and during IV infusion of phenylephrine, were constructed as described previously for RSNA (17, 18) . The intercept of the linear regression line with the diastolic blood pressure axis was used to assess shifts in the baroreflex relations and differences in the slopes were used to assess differences in baroreflex sensitivity. The control baroreflex relation was determined by 
RESULTS
CSNA was pulse-related and was blocked by ganglion blockade with hexamethonium, indicating that the recordings were of post-ganglionic, efferent sympathetic nerve activity (data not shown).
Effect of ICV losartan on the responses to ICV Ang II
In 6 conscious sheep, CSNA increased progressively during the 30 minute ICV infusion of Ang II (3 nmol/h), reaching a maximum of 23±7% above control (P<0.001) (Figs 1 and 2 ).
Over the infusion period Ang II increased MAP from 89±1.8 to 97±2.1 mmHg (P<0.001), but did not change HR. These responses to Ang II were prolonged, taking about 45 minutes to return to control. ICV infusion of losartan for one hour before administration of Ang II had no effect on CSNA or MAP. The increases in CSNA and MAP in response to Ang II were blocked by ICV infusion of losartan. ICV infusion of CSF for 30 minutes had no effect on CSNA, MAP or HR (n=7).
Effect of ICV losartan on the responses to ICV hypertonic saline
In 7 conscious sheep, ICV infusion of hypertonic saline caused a gradual increase in CSNA (P<0.05), reaching a maximum increase of 9.4±6.6% at the end of the 20 minute infusion period (Fig. 3 ). This was accompanied by an increase in MAP from 87±2 to 92±2 mmHg (P<0.01) but there was no change in HR. Both CSNA and MAP returned to control levels over the next 20 minutes.
ICV infusion of losartan for 1 hour had no significant effects on CSNA or MAP. At the end of the infusion CSNA was 97 ± 5% of control and MAP was 87 ±3 compared with 88 ± 3 mmHg before infusion. Losartan inhibited the increase in CSNA and MAP in response to ICV hypertonic saline (Fig. 3) . Central administration of sorbitol (1.2 M in CSF) for 20 minutes, an osmotic control for hypertonic saline, had no significant effects on CSNA or MAP (n=5).
Baroreflex relations
The slopes and intercepts of the baroreflex relations between CSNA and diastolic blood pressure were the same regardless of whether they were obtained from spontaneous fluctuations during ICV infusion of CSF or during IV infusion of phenylephrine (n=6) ( (Fig. 4B) . With ICV hypertonic saline, there was a non-significant trend towards a greater intercept (91.7 ± 3.2 vs 90.4 ± 2.9 mmHg) with no change in the slope of the relation (-11.9 ± 1.6 vs -11.1 ± 1.4 % change/mmHg) (n=8) (Fig.   4C ).
DISCUSSION
This is one of the very few studies to examine the control of CSNA in conscious animals and the first to directly investigate the control of CSNA by central angiotensinergic mechanisms.
The main findings of this study are that ICV infusion of Ang II or hypertonic saline increased CSNA. This occurred despite the increase in arterial pressure that normally causes baroreceptor-induced inhibition of CSNA. These responses, an increase in CSNA and MAP, were inhibited by losartan, indicating that they were mediated by angiotensin AT-1 receptors.
There is extensive evidence that sympathetic activity to individual organs is controlled differentially. In a number of elegant studies in conscious cats, Ninomiya and Matsukawa simultaneously recorded CSNA and RSNA and demonstrated a lack of concordance between bursts in the two nerves, different respiratory modulation of CSNA and RSNA in a given respiratory cycle and a greater initial response of RSNA than CSNA with exercise (24, 25) . In anesthetised animals, activation of left atrial receptors caused an increase in CSNA, a decrease in RSNA and no effect on lumbar and splenic nerve activities (11) . The present findings that ICV infusion of Ang II and hypertonic saline increased CSNA, in contrast to our previous findings that these stimuli caused profound and sustained renal sympatho-inhibition (17, 18) , are further examples of the differential control of CSNA and RSNA. In addition, the rightward shift of the baroreflex relation between CSNA and diastolic pressure during central infusion of Ang II is in striking contrast to the leftward shift in the relation between RSNA and diastolic pressure caused by this stimulus (17, 18) .
The ICV Ang II-induced increases in CSNA and MAP were prevented by losartan, indicating that these responses depended on stimulation of Ang II AT-1 receptors. Losartan also inhibited the increase in CSNA in response to hypertonic saline, indicating a role for angiotensin AT-1 receptors. This is in accord with other findings that have shown that central administration of hypertonic saline elicits a losartan-sensitive range of responses (1, 18, 23, 30) . The finding from a m icrodialysis study that perfusion of the paraventricular nucleus of the hypothalamus with hypertonic saline increased release of angiotensin is further support that the actions of hypertonic saline are mediated by angiotensin (27) . In the present study, the effect of hypertonic saline on CSNA was not mimicked by ICV infusion of hypertonic sorbitol, implicating cerebral sodium (or chloride) sensors rather than osmoreceptors. This is in accord with previous findings that ICV infusions of hypertonic saline are more effective at inducing osmoregulatory responses than osmotically equivalent saccharide solutions (22) .
The present finding that central administration of Ang II increased MAP, but did not decrease HR, is in agreement with our previous findings (17) and those of others in conscious rats (4) and conscious rabbits (29) . The observation that ICV Ang II increased CSNA indicates that the absence of a baroreceptor-induced bradycardia is not only due to inhibition of efferent vagal discharge by Ang II, but is also due to its action to increase CSNA. The fact that during ICV Ang II there was no increase in heart rate, despite the increase in CSNA, suggests that vagal tone increased, although there is evidence that the extent of the increase in vagal tone to the heart is attenuated by angiotensin (4). These effects of Ang II on the baroreflex control of heart rate have important physiological actions as they result in greater increases in arterial pressure for any degree of peripheral vasoconstriction.
The site of action of Ang II to cause this increase in CSNA cannot be determined from these studies of ICV infusions, but findings from other studies indicate that the lamina terminalis is a probable site (19) (3). The laminal terminalis, which is situated in the anterior wall of the third ventricle, consists of the subfornical organ, median preoptic nucleus and organum vasculosum of the lamina terminalis (OVLT). It is important to note that the responses to Ang II in the present study result from its actions behind the blood-brain-barrier, suggesting that the median preoptic nucleus is a likely site of action as the other two nuclei within the lamina terminalis are circumventricular organs. Evidence supporting a role for the lamina terminalis in the central responses to Ang II is the finding that it contains a high density of ANG II receptors in the sheep (20) and that the neural activation marker c-fos is expressed in the lamina terminalis of rats after central administration of ANG II (21) . Furthermore, lesion of the lamina terminalis blocked the increase in MAP and inhibition of RSNA in response to ICV Ang II and hypertonic saline (19) .
Perspectives
It has been suggested that central angiotensinergic mechanisms may play a critical role in the increase in sympathetic activity that occurs in heart failure. In conscious rats, ICV administration of losartan returned basal RSNA and the reflex control of RSNA towards normal (5) . To date the effect of central AT-1 receptor blockade on CSNA has not been studied in heart failure, but our finding that ICV Ang II increases CSNA indicates that it is possible that overactivity of the central Ang II system may contribute to the large increase in CSNA reported in heart failure. There is evidence from studies of norepinephrine spillover in patients with heart failure that sympathetic drive to the heart increases before that to other organs (31) and that in established heart failure the increase in cardiac norepinephrine spillover is greater than that to other organs (6). Our findings that Ang II increases CSNA, but decreases RSNA, indicates that overactivity of this system could be one of the causes of a preferential increase in sympathetic activity to the heart compared with other organs. 
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